Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
35
FDMT Quote, Financials, Valuation and Earnings
Last price:
$4.35
Seasonality move
:
-28.07%
Day range:
$4.20 - $4.34
52-week range:
$2.24 - $28.93
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
10,289.90x
P/B ratio:
0.42x
Volume:
319.7K
Avg. volume:
444.5K
1-year change:
-84.07%
Market cap:
$197.3M
Revenue:
$37K
EPS (TTM):
-$3.18
Analysts' Opinion
-
Consensus Rating4D Molecular Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 2 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $31.10, 4D Molecular Therapeutics has an estimated upside of 630.05% from its current price of $4.26.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $10.00 representing 100% downside risk from its current price of $4.26.
Fair Value
-
According to the consensus of 8 analysts, 4D Molecular Therapeutics has 630.05% upside to fair value with a price target of $31.10 per share.
FDMT vs. S&P 500
-
Over the past 5 trading days, 4D Molecular Therapeutics has underperformed the S&P 500 by -3.68% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
4D Molecular Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
4D Molecular Therapeutics revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter 4D Molecular Therapeutics reported revenues of $14K.
Earnings Growth
-
4D Molecular Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter 4D Molecular Therapeutics reported earnings per share of -$0.86.
Enterprise value:
-124.1M
EV / Invested capital:
--
Price / LTM sales:
10,289.90x
EV / EBIT:
--
EV / Revenue:
-5,395.40x
PEG ratio (5yr expected):
-0.04x
EV / Free cash flow:
0.79x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-30.11%
Net Income Margin (TTM):
-767126.09%
Return On Equity:
-32.41%
Return On Invested Capital:
-32.41%
Operating Margin:
-383007.14%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $2.2M | $20.5M | $23K | $28K | $14K | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$113.7M | -$120.9M | -$203.3M | -$38.1M | -$53.6M | |
| EBITDA | -$109.2M | -$115M | -$196.5M | -$36.5M | -$51.9M | |
| Diluted EPS | -$3.38 | -$2.44 | -$3.18 | -$0.66 | -$0.86 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $264.5M | $243M | $207M | $535.6M | $332.6M | |
| Total Assets | $270.1M | $324.9M | $244M | $629.9M | $515.7M | |
| Current Liabilities | $13.9M | $12.1M | $11.3M | $16.4M | $26.9M | |
| Total Liabilities | $27.7M | $28.9M | $25.4M | $29.3M | $46M | |
| Total Equity | $242.4M | $296.1M | $218.6M | $600.6M | $469.7M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$91M | -$77M | -$153.3M | -$29.1M | -$47.8M | |
| Cash From Investing | $80.2M | -$190.7M | -$7.2M | -$263.3M | $31.9M | |
| Cash From Financing | $13.5M | $464.7M | $18.4M | $318.8M | -- | |
| Free Cash Flow | -$97.2M | -$79.4M | -$157M | -$29.8M | -$48.4M | |
FDMT
Sector
Market Cap
$197.3M
$34.4M
Price % of 52-Week High
14.73%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
-10.49%
-1.01%
1-Year Price Total Return
-84.08%
-37.36%
Beta (5-Year)
--
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$4.25
200-day SMA
Sell
Level
$5.50
Bollinger Bands (100)
Buy
Level
3.19 - 4.31
Chaikin Money Flow
Buy
Level
88.5K
20-day SMA
Buy
Level
$4.13
Relative Strength Index (RSI14)
Buy
Level
53.44
ADX Line
Buy
Level
16.13
Williams %R
Neutral
Level
-29.2683
50-day SMA
Buy
Level
$3.88
MACD (12, 26)
Buy
Level
1.17
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
462.4K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.3979)
Sell
CA Score
(Annual)
Level (-0.4688)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (3.7093)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
Stock Forecast FAQ
In the current month, FDMT has received 5 Buy ratings 2 Hold ratings, and 1 Sell ratings. The FDMT average analyst price target in the past 3 months is $31.10.
-
Where Will 4D Molecular Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that 4D Molecular Therapeutics share price will rise to $31.10 per share over the next 12 months.
-
What Do Analysts Say About 4D Molecular Therapeutics?
Analysts are divided on their view about 4D Molecular Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that 4D Molecular Therapeutics is a Sell and believe this share price will drop from its current level to $10.00.
-
What Is 4D Molecular Therapeutics's Price Target?
The price target for 4D Molecular Therapeutics over the next 1-year time period is forecast to be $31.10 according to 8 Wall Street analysts, 5 of them rate the stock a Buy, 1 rates the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is FDMT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for 4D Molecular Therapeutics is a Buy. 5 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of FDMT?
You can purchase shares of 4D Molecular Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase 4D Molecular Therapeutics shares.
-
What Is The 4D Molecular Therapeutics Share Price Today?
4D Molecular Therapeutics was last trading at $4.35 per share. This represents the most recent stock quote for 4D Molecular Therapeutics. Yesterday, 4D Molecular Therapeutics closed at $4.26 per share.
-
How To Buy 4D Molecular Therapeutics Stock Online?
In order to purchase 4D Molecular Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
